Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

98°
- Benton, AR (72018)
  Today
  
  Clear skies. Low near 70F. Winds light and variable..
  
  Tonight
  
  Clear skies. Low near 70F. Winds light and variable.
  
  Updated: September 17, 2026 @ 5:28 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2026
Community Calendar

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.20 -0.12 (-0.90%)

Delayed Quote Updated: 3:56 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

21 22 Next >

5 Beaten-Down Stocks That Could Soar in 2024 ↗

December 16, 2023

These players may offer your portfolio a lift as early as next year. But most importantly, they could excel over time.

Via The Motley Fool

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Via InvestorPlace

Could Intellia Therapeutics Become the Next CRISPR Therapeutics? ↗

December 12, 2023

Intellia is approaching the finish line.

Via The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market ↗

November 28, 2023

These stocks may take off in a market favoring growth.

Via The Motley Fool

Analyst Ratings for Intellia Therapeutics ↗

November 10, 2023

Via Benzinga

2 Brilliant Growth Stocks to Buy and Hold Forever ↗

October 12, 2023

These two growth stocks could be genuine wealth escalators.

Via The Motley Fool

Down 45%, Is Intellia a Buy? ↗

October 10, 2023

Intellia's operating in the high-growth field of gene editing.

Via The Motley Fool

Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 20, 2023

Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 17, 2023

Via Benzinga

Why Intellia Therapeutics Stock Is Surging Tuesday ↗

November 14, 2023

Intellia Therapeutics Inc (NYSE: NTLA) shares are trading higher Tuesday after the company announced it received European Union orphan d

Via Benzinga

Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock ↗

November 13, 2023

Via Benzinga

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Via InvestorPlace

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years ↗

November 02, 2023

Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.

Via The Motley Fool

Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy? ↗

October 28, 2023

There's more to being a good investment than doing groundbreaking science.

Via The Motley Fool

3 Stocks Cathie Wood Is Buying That Should Be on Your List Too ↗

October 23, 2023

The three companies are positioned to benefit from red-hot trends.

Via The Motley Fool

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time ↗

October 21, 2023

Wood is going all in on gene editing.

Via The Motley Fool

Cathie Wood's Ark Offloads $6.3M In Tesla Shares Amid EV Maker's Q3 Earnings Disappointment ↗

October 18, 2023

Via Benzinga

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying ↗

October 16, 2023

These two large-cap biopharma companies could have more room to run.

Via The Motley Fool

2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years ↗

October 14, 2023

These two gene-editing stocks could be diamonds in the rough.

Via The Motley Fool

Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row ↗

October 11, 2023

Via Benzinga

Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares ↗

October 10, 2023

Via Benzinga

This Cathie Wood Stock Is Poised to Double, Says Wall Street ↗

October 10, 2023

Almost anything is possible in the volatile biotech industry.

Via The Motley Fool

Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy? ↗

October 03, 2023

Don't bet the farm on the analysts being right -- but they might be.

Via The Motley Fool

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

October 03, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals ↗

September 23, 2023

Rocket could launch its medicines sooner, but Intellia is aiming for larger markets.

Via The Motley Fool

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Sections

Services

Follow Us